IJPR  artciles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 1.55 (2012 - 2016). 

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
Protective Role of DPP-IV Inhibitors Against Isoproterenol Induced Myocardial Ischemia in rats

Author: RUTVI VAIDYA, DR. BHAVIN VYAS, KRISHNA K. PAREKH, DR. SHAILESH SHAH
Abstract: Dipeptidyl Peptidase-IV (DPP-IV, DPP-4) is an enzyme belonging to cell-surface peptidase group of cell-surface proteases that is involved in the regulation of the biological activity of small bioactive peptides that serve in cell communication, namely peptide hormones, neuropeptides, growth factors, or cytokines. DPP4 transmits signals across cell membranes and interacts with other membrane proteins. Regulatory peptides, chemokines, neuropeptides and several other molecules are substrate for DPP-IV. This precipitates its contribution in various pathophysiological condition and disorders. Inhibition of DPP-IV enzyme, prevents cleavage or deactivation of its substrate endogenous molecules such as GLP-1, SDF-1, anti-oxidant substances, growth factors and various chemokines. DPP-IV inhibition provides protective as well as curative effect due to intact activity of endogenous substances. In the present study protective role of synthetic DPP-IV (sitagliptin, linagliptin, alogliptin) was evaluated against isoproterenol hydrochloride induced myocardial ischemic injury in rats by estimation of cardiac biomarkers (CK-MB and SDF-1a) and biochemical antioxidant parameters (Superoxide Dismutase(SOD), Catalase, Lipid peroxide(LPO)) along with Macroscopic enzyme mapping and histopathology analysis compared between control, model control and treatment groups. The results showed marked decrease in level of CK-MB and LPO and increase in level of SDF-1a and other anti-oxidants. Macroscopic enzyme mapping grossly indicated less infarct area in treatment group as compared to model control group. Histology showed no significant pathogenesis in DPP-IV inhibitor treated group unlike model control group. The results describes cardioprotective role of DPP-IV inhibitors by precipitating preventive effect against isoproterenol induced myocardial ischemic injury.
Keyword: DPP-IV inhibitor, cardioprotection, SDF-1a, myocardial ischemic injury
Download: Request For Article
 












USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events

2017: 6.457
2016: 5.999
2015: 5.406
2014: 5.099

CiteScore 2016 -  0.09

SJR 2016 - 0.111

SNIP 2016 - 0.055

Impact Factor for five years is 1.55 (2012 - 2016)
Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477
Impact Factor for five years is 1.3 (2010 - 2014)